Development of an m6A-Related lncRNAs Signature Predicts Tumor Stemness and Prognosis for Low-Grade Glioma Patients

• Published in: Stem cells international Vol. 2024; no. 1; p. 2062283
• Main Authors: Xu, Dahua, Li, Peihu, Zhang, Chunrui, Shen, Yutong, Cai, Jiale, Wei, Qingchen, Cao, Meng, Xu, Zhizhou, Wu, Deng, Wang, Hong, Bi, Xiaoman, Wang, Bo, Li, Kongning
• Format: Journal Article
• Language: English
• Published: United States Hindawi 2024; John Wiley & Sons, Inc; Wiley
• Subjects: Algorithms; Analysis; Brain tumors; Cancer; Datasets; Gene expression; Genomes; Glioma; Gliomas; Medical prognosis; Medical research; Medicine, Experimental; Methyltransferases; Microenvironments; Mutation; N6-methyladenosine; Nomograms; Non-coding RNA; Patients; Prognosis; Regression analysis; Risk analysis; Risk groups; Stem cells; Transcriptomes; Tumorigenesis; Tumors; China
• ISSN: 1687-966X; 1687-9678; 1687-9678
• DOI: 10.1155/2024/2062283

Background. Growing evidence has revealed that m6A modification of long noncoding RNAs (lncRNAs) dynamically controls tumor stemness and tumorigenesis-related processes. However, the prognostic significance of m6A-related lncRNAs and their associations with stemness in low-grade glioma (LGG) remain to be clarified. Methods. A multicenter transcriptome analysis of lncRNA expression in 1,247 LGG samples was performed in this study. The stemness landscape of LGG tumors was presented and associations with clinical features were revealed. The m6A-related lncRNAs were identified between stemness groups and were further prioritized via least absolute shrinkage and selection operator Cox regression analysis. A risk score model based on m6A-related lncRNAs was constructed and validated in external LGG datasets. Results. Based on the expression of LINC02984, PFKP-DT, and CRNDE, a risk model and nomogram were constructed; they successfully predicted the survival of patients and were extended to external datasets. Significant correlations were observed between the risk score and tumor stemness. Moreover, patients in different risk groups exhibited distinct tumor immune microenvironments and immune signatures. We finally provided several potential compounds suitable for specific risk groups, which may aid in LGG treatment. Conclusions. This novel signature presents noteworthy value in the prediction of prognosis and stemness status for LGG patients and will foster future research on the development of clinical regimens.